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BACKGROUND
Ticagrelor may be a more effective antiplatelet therapy than aspirin for the preven-
tion of recurrent stroke and cardiovascular events in patients with acute cerebral 
ischemia.
METHODS
We conducted an international double-blind, controlled trial in 674 centers in 33 
countries, in which 13,199 patients with a nonsevere ischemic stroke or high-risk 
transient ischemic attack who had not received intravenous or intraarterial throm-
bolysis and were not considered to have had a cardioembolic stroke were ran-
domly assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive 
either ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for 
days 2 through 90) or aspirin (300 mg on day 1 followed by 100 mg daily for days 
2 through 90). The primary end point was the time to the occurrence of stroke, 
myocardial infarction, or death within 90 days.
RESULTS
During the 90 days of treatment, a primary end-point event occurred in 442 of the 
6589 patients (6.7%) treated with ticagrelor, versus 497 of the 6610 patients (7.5%) 
treated with aspirin (hazard ratio, 0.89; 95% confidence interval [CI], 0.78 to 1.01; 
P = 0.07). Ischemic stroke occurred in 385 patients (5.8%) treated with ticagrelor 
and in 441 patients (6.7%) treated with aspirin (hazard ratio, 0.87; 95% CI, 0.76 to 
1.00). Major bleeding occurred in 0.5% of patients treated with ticagrelor and in 
0.6% of patients treated with aspirin, intracranial hemorrhage in 0.2% and 0.3%, 
respectively, and fatal bleeding in 0.1% and 0.1%.
CONCLUSIONS
In our trial involving patients with acute ischemic stroke or transient ischemic 
attack, ticagrelor was not found to be superior to aspirin in reducing the rate of 
stroke, myocardial infarction, or death at 90 days. (Funded by AstraZeneca; 
ClinicalTrials.gov number, NCT01994720.)
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Ischemic stroke and transient ische­mic attack are common, and the risk of sub-sequent ischemic events is particularly high 
during the first 90 days after the index cerebro-
vascular event.1-4 Aspirin at a dose of 50 to 325 
mg daily is commonly used in this context.5-7 
However, the benefit of aspirin in the secondary 
prevention of ischemic stroke is limited; even 
with concurrent aspirin treatment, the rate of 
recurrent stroke is 10 to 15% in the first 90 days, 
and the rate of new ischemic events when aspi-
rin is used in the long term is only 22% lower 
than the rate associated with no preventive treat-
ment.8 Furthermore, even moderate doses of aspi-
rin are associated with relative risks of hemor-
rhagic events, including gastrointestinal bleeding, 
that range from 1.5 to 3.1.9 More intensive anti-
platelet therapy through a different mechanism 
of action may be more effective than aspirin at 
reducing the risk of recurrent ischemia after tran-
sient ischemic attack or acute ischemic stroke, 
but evidence to support this is limited.10,11 Tica-
grelor is a potent antiplatelet agent that revers-
ibly binds and inhibits the P2Y12 receptor on 
platelets and is direct-acting, in contrast to 
clopidogrel, the action of which is dependent on 
variable and genetically determined metabolic 
activation.12,13 The Acute Stroke or Transient Is-
chae mic Attack Treated with Aspirin or Tica-
grelor and Patient Outcomes (SOCRATES) trial 
was designed to compare ticagrelor with aspirin 
with regard to their effectiveness for the preven-
tion of major vascular events (a composite of 
stroke [ischemic or hemorrhagic], myocardial in-
farction, or death) over a period of 90 days in the 
treatment of patients with acute cerebral ischemia.
Me thods
Study Design and Oversight
SOCRATES was a multicenter, randomized, dou-
ble-blind, double-dummy, parallel-group trial; 
patients were enrolled from January 7, 2014, 
through October 29, 2015, at 674 sites in 33 
countries. The trial was approved by the relevant 
ethics committee at each participating site. The 
protocol, analysis plan, and descriptions of the 
trial leadership, committees, investigators, and 
sites are provided in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org. Details of the study rationale, design, 
and methods have been described previously.14
The executive committee was responsible for 
the overall design, interpretation, and supervi-
sion of the trial, including the development of 
the protocol and any protocol amendments. The 
executive committee was also responsible for 
ensuring the integrity of the data, analysis, and 
presentation of results.
An independent data and safety monitoring 
committee reported to the executive committee. 
It regularly assessed safety outcomes, overall study 
integrity, and study conduct, at intervals based 
on the number of patients who had completed 
the 90-day treatment period throughout the trial, 
and oversaw a single interim analysis. An inde-
pendent clinical-event adjudication committee, the 
members of which were unaware of the treat-
ment assignments, adjudicated the primary and 
secondary efficacy end points and all bleeding 
events that were not reported as minimal.
The study was sponsored by AstraZeneca, 
which collaborated in the execution of the trial 
and collected the data. All authors had full ac-
cess to the data and the data analysis. The 
analyses were performed by AstraZeneca under 
the direction of the executive committee. The 
executive committee made the decision to sub-
mit the manuscript for publication. The authors 
vouch for the accuracy and completeness of the 
data and data analyses and the fidelity of this 
report to the study protocol. The first author 
wrote the first draft of the manuscript, which 
was edited by all the other authors.
Study Population
Eligible patients had an acute ischemic stroke 
with a National Institutes of Health Stroke Scale 
(NIHSS) score of 5 or lower (scores range from 
0 to 42, with higher scores indicating more se-
vere stroke) or high-risk transient ischemic at-
tack (ABCD2 stroke risk score of ≥4 [scores range 
from 0 to 7 with higher scores indicating higher 
risk of stroke] or symptomatic intracranial or 
extracranial arterial stenosis) and could undergo 
randomization within 24 hours after symptom 
onset, were at least 40 years of age, and had 
undergone a computed tomographic (CT) or 
magnetic resonance imaging (MRI) scan before 
randomization to rule out intracranial bleeding 
or other conditions that could account for the 
neurologic symptoms or contraindicate study 
treatment. The components of the ABCD2 stroke 
risk score are age, blood pressure, clinical fea-
A Quick Take 
is available at 
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tures, duration of transient ischemic attack, and 
presence or absence of diabetes.
Patients were not eligible for participation if 
other specific antiplatelet therapy or anticoagu-
lation therapy was planned or if carotid, cerebro-
vascular, or coronary revascularization was planned 
that would require halting study treatment with-
in 7 days after randomization. Patients were also 
not eligible if they had hypersensitivity to ti-
cagrelor or aspirin; had a history of atrial fibril-
lation, ventricular aneurysm, or suspicion of car-
dioembolic cause for transient ischemic attack 
or stroke; underwent intravenous or intraarte-
rial thrombolysis or mechanical thrombectomy 
within 24 hours before randomization; were in 
need of therapy with strong cytochrome P-450 
3A (CYP3A) inhibitors or CYP3A substrates with 
narrow therapeutic indexes; required treatment 
with nonsteroidal antiinflammatory drugs for 
more than 7 consecutive days; had a known 
bleeding diathesis or coagulation disorder; had 
a history of symptomatic nontraumatic intrace-
rebral hemorrhage at any time, gastrointestinal 
bleed within the past 6 months, or major sur-
gery within 30 days; had severe liver disease; 
had renal failure requiring dialysis; were preg-
nant or lactating; or could not understand or 
comply with study procedures or follow-up. 
Written informed consent was obtained before 
any study-specific procedures were performed. 
Additional information on the inclusion and ex-
clusion criteria are provided in the Supplementary 
Appendix.
Treatment
Within 24 hours after the onset of symptoms of 
acute ischemic stroke or transient ischemic at-
tack, eligible patients were randomly assigned to 
a treatment group with the use of an interactive 
telephone and Web-based system. The loading 
dose was to be given as soon as possible after 
randomization. Eligible patients were randomly 
assigned in a 1:1 ratio to one of two treatment 
groups. Patients received either ticagrelor (a 
loading dose of 180 mg given as two 90-mg 
tablets on day 1, followed by 90 mg twice daily 
given orally together with loading and daily 
doses of aspirin placebo) or aspirin (a loading 
dose of 300 mg given as three 100-mg tablets on 
day 1, followed by 100 mg daily given orally to-
gether with a loading dose and twice-daily doses 
of ticagrelor placebo). Subsequent maintenance 
doses were taken in the morning and evening, at 
approximately 12-hour intervals, for the remain-
der of the 90-day treatment period. The loading 
and maintenance doses of ticagrelor were se-
lected on the basis of data from previous phase 
2–3 clinical studies. At the end of 90 days of 
study treatment, patients were treated at the 
discretion of the investigator and followed for an 
additional 30 days.
End Points
The primary end point for the trial was the time 
from randomization to the first occurrence of 
any event from the composite of stroke (isch-
emic or hemorrhagic), myocardial infarction, or 
death; each component of the composite end 
point was based on standard definitions.14 The 
predefined secondary end point, to be tested in 
a hierarchical testing sequence if the difference 
between the treatment groups with regard to the 
primary end point was significant, was the time 
to ischemic stroke. Other, exploratory secondary 
end points included the time to net clinical out-
come, defined as the composite of stroke, myo-
cardial infarction, death, or life-threatening 
bleeding; the composite of cardiovascular death, 
myocardial infarction, or ischemic stroke; all 
strokes, disabling strokes, and fatal strokes in-
dividually; and death from any cause, death 
from cardiovascular causes, and myocardial in-
farction individually. The full list of prespecified 
end points is provided in the study protocol.
The safety end points included time to first 
major bleeding event, assessed with the use of 
the PLATO bleeding definition (see the Supple-
mentary Appendix)15; time to discontinuation of 
study treatment as a result of any bleeding event; 
incidence of intracranial hemorrhage; incidence 
of fatal bleeding; and incidence of serious and 
selected nonserious adverse events.
Statistical Analysis
The trial was event-driven. To detect a hazard 
ratio of 0.80 with a final two-sided significance 
level of 4.98% and 88.7% power, a total of 844 
primary end-point events were required. The 
significance level was adjusted from 5.00% to 
account for a single interim analysis for efficacy 
and futility that was performed when half the 
primary end-point events had been observed. On 
the basis of the pooled observed event rate, the 
sample size was recalculated during the trial 
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from 9600 to 13,200 patients to accrue the tar-
get number of primary events.14
All efficacy analyses were based on the inten-
tion-to-treat principle and included the full 
analysis set of patients with adjudicated events. 
Safety analyses were performed with the cohort 
that received treatment. The secondary end 
point, time to first ischemic stroke, was to be 
tested for confirmation only if the results of the 
primary analysis were significant. The analyses 
of other prespecified end points were explor-
atory. The time from randomization to the first 
occurrence of any event for a given end point 
was compared with the use of the Cox propor-
tional hazards model. Interactions between 
treatment assignment and prespecified sub-
groups were evaluated by including terms for 
treatment, subgroup, and treatment-by-subgroup 
interaction in the Cox model. Interaction terms 
with a P value of less than 0.05 were considered 
to be statistically significant.
R esult s
Patient Population
Overall, 13,307 patients were enrolled, and 
13,199 patients underwent randomization (Fig. 
1). A total of 494 patients (3.7%) presented with 
ischemic stroke within 4.5 hours after symptom 
onset, of whom 128 (1.0% of the total patient 
population) had an NIHSS score higher than 3. 
Two patients were lost to follow-up, and we were 
unable to determine the vital status of 7 others 
after they withdrew their consent. Event statuses 
for components of the primary end point were 
ascertained for 98.5% of the potential patient 
follow-up time (see Table S1 in the Supplemen-
tary Appendix for a description of patient visits). 
The characteristics of the patients at baseline are 
presented in Table 1 and in Table S2 in the 
Supplementary Appendix.
Primary and Secondary End Points
A primary composite end-point event occurred 
in 442 of the 6589 patients (6.7%) in the ticagre-
lor group and in 497 of the 6610 patients (7.5%) 
in the aspirin group (hazard ratio, 0.89; 95% 
confidence interval [CI], 0.78 to 1.01; P = 0.07) 
(Fig. 2A and Table 2). On the basis of our hier-
archical testing plan, all analyses of secondary 
end points were therefore considered to be ex-
ploratory and were not used to make conclusions 
regarding significance. The main secondary end 
point, ischemic stroke, occurred in 385 patients 
(5.8%) in the ticagrelor group and 441 patients 
(6.7%) in the aspirin group (hazard ratio, 0.87; 
95% CI, 0.76 to 1.00; nominal P = 0.046) (Fig. 2B 
and Table 2). Other secondary end points are 
reported in Table 2. There were no treatment-by-
subgroup interactions in the prespecified sub-
groups (P>0.05 for all comparisons) (Fig. 3).
Figure 1. Enrollment and Randomization of Patients.
One patient who was randomly assigned to the ticagrelor group accidental-
ly received aspirin during the entire treatment period; in accordance with 
the protocol, this patient was included in the ticagrelor group for the pri-
mary efficacy analysis and was included in the aspirin group in the safety 
analysis.
13,199 Underwent randomization
13,307 Patients gave written informed
consent and were enrolled
108 Were excluded
93 Were not eligible
15 Withdrew
6589 Were assigned to receive 
ticagrelor, twice daily
6550 (99.4%) Received at least
1 dose
39 Never received a dose
6610 Were assigned to aspirin
therapy, once daily
6580 (99.5%) Received at least 
1 dose
30 Never received a dose
1148 (17.5%) Had premature perma-
nent drug discontinuation
621 Had adverse event or severe
adverse event
270 Decided to stop treatment
19 Were nonadherent to study
protocol
238 Had other reasons, including
primary end-point events
965 (14.7%) Had premature perma-
nent drug discontinuation
452 Had adverse event or severe
adverse event
259 Decided to stop treatment
13 Were nonadherent to study
protocol
241 Had other reasons, including
primary end-point events
6542 (99.3%) Were in the study at the
end-of-treatment visit
44 (0.7%) Withdrew consent
4 Had unknown vital status
6554 (99.2%) Were in the study at the
end-of-treatment visit
53 (0.8%) Withdrew consent
3 Had unknown vital status
2 Were lost to follow-up
6589 Were included in primary efficacy
analysis
6549 Were included in primary
safety analysis
39 Were excluded because they 
never received study drug
6610 Were included in primary efficacy
analysis
6581 Were included in primary
safety analysis
30 Were excluded because they
never received study drug
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Characteristic
Ticagrelor 
(N = 6589)
Aspirin 
(N = 6610)
Age — yr 65.8±11.23 65.9±11.37
Female sex — no. (%) 2759 (41.9) 2724 (41.2)
Race — no. (%)†
White 4374 (66.4) 4410 (66.7)
Black 119 (1.8) 120 (1.8)
Asian 1957 (29.7) 1949 (29.5)
Other 139 (2.1) 131 (2.0)
Ethnic background — no. (%)†
Not Hispanic 6023 (91.4) 6050 (91.5)
Hispanic 566 (8.6) 558 (8.4)
Region — no. (%)
Asia or Australia 1990 (30.2) 1981 (30.0)
Europe 3769 (57.2) 3772 (57.1)
North America 514 (7.8) 540 (8.2)
Central or South America 316 (4.8) 317 (4.8)
Median blood pressure (interquartile range) — mm Hg
Systolic 150 (137.0–165.0) 150 (135.5–165.0)
Diastolic 84 (78.0–92.0) 84 (77.0–91.0)
Median body-mass index (interquartile range)‡ 26.1 (23.5–29.4) 26.0 (23.5–29.3)
Medical history — no. (%)
Hypertension 4797 (72.8) 4933 (74.6)
Dyslipidemia 2531 (38.4) 2497 (37.8)
Diabetes mellitus 1664 (25.3) 1548 (23.4)
Previous ischemic stroke 765 (11.6) 828 (12.5)
Previous TIA 410 (6.2) 446 (6.7)
Previous myocardial infarction 280 (4.2) 268 (4.1)
Coronary artery disease 573 (8.7) 571 (8.6)
Congestive heart failure 234 (3.6) 248 (3.8)
Taking aspirin before randomization — no. (%) 2130 (32.3) 2102 (31.8)
Taking clopidogrel before randomization — no. (%) 219 (3.3) 237 (3.6)
Time to randomization after onset of symptoms — no. (%)
<12 hr 2400 (36.4) 2424 (36.7)
≥12 hr 4188 (63.6) 4186 (63.3)
Qualifying event — no. (%)
TIA 1790 (27.2) 1741 (26.3)
Ischemic stroke 4798 (72.8) 4869 (73.7)
Baseline ABCD2 score among patients with TIA as qualifying event 
— no./total no. (%)§
≤5 1313/1790 (73.4) 1257/1741 (72.2)
>5 471/1790 (26.3) 479/1741 (27.5)
Baseline NIHSS score among patients with ischemic stroke as 
qualifying event — no./total no. (%)¶
≤3 3235/4798 (67.4) 3282/4869 (67.4)
>3 1541/4798 (32.1) 1566/4869 (32.2)
*  The differences in baseline characteristics between the treatment groups were not significant, with the exception of the pro-
portions of patients with a history of diabetes or hypertension (nominal P<0.05). TIA denotes transient ischemic attack.
†  Race and ethnic background were self-reported.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  ABCD2 stroke risk scores range from 0 to 7, with higher scores indicating higher risk; data are provided only for the 
group of 3531 patients for whom TIA was the qualifying event for inclusion in the trial.
¶  National Institutes of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating more se-
vere stroke; data are provided only for the group of 9667 patients for whom ischemic stroke was the qualifying event  
for inclusion in the trial.
Table 1. Baseline Characteristics of the Participants.*
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Safety
A primary safety end-point event (PLATO-defined 
major bleeding) occurred in 31 patients (0.5%) 
in the ticagrelor group and 38 patients (0.6%) in 
the aspirin group (hazard ratio, 0.83; 95% CI, 
0.52 to 1.34) (Fig. 2C and Table 2). Intracranial 
hemorrhage occurred in 12 patients (0.2%) in the 
ticagrelor group and in 18 patients (0.3%) in the 
aspirin group. Fatal bleeding occurred in 9 pa-
tients (0.1%) in the ticagrelor group and in 4 pa-
tients (0.1%) in the aspirin group. Similarly, 
there were no significant differences in the other 
major safety outcomes (Table 2, and Table S3 in 
the Supplementary Appendix). Dyspnea was more 
common in the ticagrelor group than in the as-
pirin group (6.2% vs. 1.4%). Permanent discon-
tinuation of study treatment occurred in 17.5% 
of patients in the ticagrelor group, versus 14.7% 
of patients in the aspirin group (Fig. 1). Dyspnea 
and bleeding events were the most frequent fac-
tors accounting for the difference, with rates of 
discontinuation due to dyspnea in the ticagrelor 
and aspirin groups of 1.4% and 0.3%, respec-
tively, and rates of discontinuation due to any 
bleeding of 1.3% and 0.6%. Serious adverse 
events and adverse events leading to discontinu-
ation of study treatment are listed in Tables S3 
and S4 in the Supplementary Appendix. A net 
clinical outcome, defined as a composite of 
stroke, myocardial infarction, death, or life-
threatening bleeding, occurred in 6.9% of pa-
tients in the ticagrelor group and 7.7% of pa-
tients in the aspirin group (hazard ratio, 0.90; 
95% CI, 0.79 to 1.02).
Discussion
In this large, international trial of secondary 
prevention in patients with noncardioembolic 
ischemic stroke and transient ischemic attack 
who underwent randomization within 24 hours 
Figure 2. Kaplan–Meier Analysis of Primary  
and Secondary End Points.
Data in Panels A and B are from the intention-to-treat 
analysis. Panel C includes events with an onset date on 
or after the date of the first dose and up to and includ-
ing 7 days after the date of the last dose of study medi-
cation. A description of PLATO-defined bleeding is 
provided in the Supplementary Appendix.
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after symptom onset and who did not receive 
thrombolytic therapy, events included in the pri-
mary end point — a composite of stroke, myo-
cardial infarction, or death — were not less 
common among patients who received ticagrelor 
than among patients who received aspirin dur-
ing the 90-day follow-up period. There was no 
evidence of a higher risk of major or intracranial 
hemorrhage with ticagrelor than with aspirin, 
but there were more instances of dyspnea and 
minor bleeding in the ticagrelor group.
In this trial, we tested the efficacy and safety 
of monotherapy with ticagrelor versus aspirin in 
patients who were treated within 24 hours after 
the onset of a cerebral ischemic event. Approxi-
mately one third of the patients were taking as-
pirin at the time of the qualifying cerebral 
ischemic event. Because the antiplatelet effects 
of aspirin typically last several days, the intro-
duction of ticagrelor represented short-term dual 
antiplatelet therapy. Subgroup analysis did not 
reveal a significant interaction indicating a ben-
efit of ticagrelor in patients who were taking 
aspirin at baseline, but further study of the com-
bination of ticagrelor and aspirin may be war-
ranted, given the possibility that the rates of 
Outcome
Ticagrelor 
(N = 6589)
Aspirin 
(N = 6610) Hazard Ratio (95% CI) P Value
no. of patients 
(%)
event 
rate*
no. of patients 
(%)
event 
rate*
Primary end point
Stroke, myocardial infarction, or death 442 (6.7) 6.8 497 (7.5) 7.5 0.89 (0.78–1.01) 0.07
Secondary end points†
Ischemic stroke 385 (5.8) 5.9 441 (6.7) 6.6 0.87 (0.76–1.00) 0.046‡
Ischemic stroke, myocardial infarction,  
or cardiovascular death
423 (6.4) 6.5 475 (7.2) 7.2 0.89 (0.78–1.01) 0.07
All stroke 390 (5.9) 6.0 450 (6.8) 6.8 0.86 (0.75–0.99) 0.03‡
Disabling stroke§ 277 (4.2) 4.2 307 (4.6) 4.7 0.90 (0.77–1.06) 0.21
Fatal stroke 18 (0.3) 0.3 17 (0.3) 0.3 1.06 (0.55–2.06) 0.86
Myocardial infarction 25 (0.4) 0.4 21 (0.3) 0.3 1.20 (0.67–2.14) 0.55
Death 68 (1.0) 1.0 58 (0.9) 0.9 1.18 (0.83–1.67) 0.36
Cardiovascular death 41 (0.6) 0.6 35 (0.5) 0.5 1.18 (0.75–1.85) 0.48
Net clinical outcome: stroke, myocardial in-
farction, death, or life-threatening 
bleeding
457 (6.9) 7.0 508 (7.7) 7.6 0.90 (0.79–1.02) 0.09
Safety end points¶
Major bleeding 31 (0.5) 0.5 38 (0.6) 0.6 0.83 (0.52–1.34) 0.45
Major bleeding, fatal or life-threatening 22 (0.3) 0.4 27 (0.4) 0.4 0.83 (0.47–1.46) 0.52
Fatal bleeding 9 (0.1) 4 (0.1)
Intracranial hemorrhage 12 (0.2) 0.2 18 (0.3) 0.3 0.68 (0.33–1.41) 0.30
Major bleeding, other 9 (0.1) 0.1 11 (0.2) 0.2 0.84 (0.35–2.03) 0.70
Major or minor bleeding 106 (1.6) 1.7 82 (1.2) 1.3 1.32 (0.99–1.76) 0.06
*  Event rates are Kaplan–Meier percentages at 90 days.
†  Ischemic stroke was the only secondary end-point event to be tested in a hierarchical testing sequence if there was a significant difference 
between the treatment groups with regard to the primary end point; analyses of all other secondary end points were prespecified but consid-
ered to be exploratory.
‡  The P value was considered nonsignificant in accordance with the hierarchical testing plan.
§  A stroke was defined as disabling if the patient had a subsequent score on the modified Rankin scale of greater than 1 (indicating death or 
any degree of disability).
¶  The safety end points involved bleeding according to the PLATO definition (see the Supplementary Appendix). A total of 6549 patients in 
the ticagrelor group and 6581 patients in the aspirin group were included in the analysis of safety outcomes.
Table 2. Efficacy and Safety Outcomes.
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Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Aspirin BetterTicagrelor Better
Overall
Age (yr)
<65
65–75
>75
Sex
Male
Female
Race
White
Black
Asian
Other
Weight
<70 kg
≥70 kg
BMI
<30
≥30
Region
Asia and Australia
Europe
North America
Central and South America
Diagnosis of index event
TIA
Ischemic stroke, NIHSS ≤3
Ischemic stroke, NIHSS >3
Time from index event to randomization
<12 hr
≥12 hr
Diabetes mellitus
Yes
No
Previous antiplatelet therapy
Yes
No
Previous ischemic stroke or TIA
Yes
No
Previous myocardial infarction
Yes
No
Previous aspirin therapy
Yes
No
Previous coronary artery disease
Yes
No
Hypertension
Yes
No
No. of
Patients Hazard Ratio (95% CI)TicagrelorSubgroup
0.92 (0.80–1.06)
0.78 (0.57–1.04)
0.89 (0.78–1.01)
0.89 (0.46–1.69)
0.96 (0.82–1.12)
0.76 (0.61–0.95)
0.89 (0.78–1.02)
0.86 (0.59–1.24)
0.91 (0.70–1.18)
0.88 (0.76–1.02)
0.88 (0.70–1.11)
0.88 (0.76–1.03)
0.80 (0.65–0.98)
0.95 (0.80–1.12)
0.81 (0.67–0.98)
0.97 (0.78–1.22)
0.87 (0.72–1.05)
1.34 (0.81–2.19)
1.14 (0.57–2.29)
0.98 (0.72–1.31)
0.84 (0.68–1.03)
0.92 (0.78–1.08)
0.83 (0.68–1.00)
0.83 (0.61–1.14)
0.91 (0.79–1.05)
0.91 (0.76–1.08)
0.87 (0.72–1.06)
0.82 (0.67–0.99)
NA
NA
0.88 (0.72–1.08)
0.96 (0.81–1.15)
0.89 (0.76–1.05)
1.16 (0.90–1.50)
0.81 (0.66–0.99)
0.89 (0.78–1.01)
0.81 (0.65–1.01)
P Value for
Interaction
13,199
6,028
4,176
2,995
7,716
5,483
8,784
239
3,906
270
5,119
7,997
10,304
2,802
3,971
7,541
1,054
633
3,531
6,517
3,107
4,824
8,374
3,212
9,981
4,716
8,483
2,321
10,872
548
12,645
4,232
8,967
1,712
11,481
9,730
3,463
Aspirin
6589 (6.7)
3021 (5.7)
2064 (7.0)
1504 (8.4)
3830 (7.0)
2759 (6.3)
4374 (5.6)
119 (3.4)
1957 (9.6)
139 (4.3)
2574 (7.8)
3978 (6.1)
5110 (7.2)
1437 (5.3)
1990 (9.6)
3769 (5.3)
514 (6.8)
316 (5.4)
1790 (4.9)
3235 (6.2)
1541 (9.8)
2400 (6.9)
4188 (6.6)
1664 (8.4)
4919 (6.1)
2358 (7.1)
4231 (6.5)
1121 (6.7)
5462 (6.7)
280 (6.4)
6303 (6.7)
2130 (6.5)
4459 (6.8)
852 (6.2)
5731 (6.8)
4797 (6.8)
1786 (6.4)
6610 (7.5)
3007 (7.0)
2112 (8.5)
1491 (7.2)
3886 (7.8)
2724 (7.2)
4410 (5.8)
120 (7.5)
1949 (11.5)
131 (5.3)
2545 (8.8)
4019 (6.6)
5194 (7.8)
1365 (6.3)
1981 (11.5)
3772 (6.0)
540 (5.2)
317 (4.7)
1741 (5.0)
3282 (7.6)
1566 (10.0)
2424 (8.5)
4186 (7.0)
1548 (9.5)
5062 (6.9)
2358 (8.4)
4252 (7.1)
1200 (8.5)
5410 (7.3)
268 (7.1)
6342 (7.5)
2102 (8.4)
4508 (7.1)
860 (7.2)
5750 (7.6)
4933 (7.7)
1677 (7.0)
0.06
0.89
0.21
0.76
0.61
0.30
0.38
0.22
0.99
0.51
0.33
0.97
0.10
0.85
0.82
total patients (% with event)
0.5 1.51.0 2.00.75
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ischemic stroke were lower in association with 
ticagrelor in this group of patients.
Although some studies have suggested that 
the risk of stroke after transient ischemic attack 
has decreased in recent years, our trial confirms 
previous studies that have shown a high risk in 
the first 2 weeks, with particularly high event 
rates in the first 2 days.1,10,16
The limitations of this trial include the lim-
ited enrollment of patients who were at espe-
cially high risk for stroke, such as those with 
high-grade carotid or severe intracranial steno-
sis. These patients may have undergone vascular 
interventions or may have been treated with the 
combination of clopidogrel plus aspirin on the 
basis of the results of the Clopidogrel in High-
Risk Patients with Acute Nondisabling Cerebro-
vascular Events (CHANCE) trial.10 The primary 
end-point event rates in the group with transient 
ischemic attack were lower than expected, which 
raises the possibility that we enrolled some pa-
tients with nonischemic conditions mimicking a 
transient ischemic attack, in whom antiplatelet 
therapy is unlikely to be efficacious. Patients 
who underwent thrombolysis or thrombectomy 
were not eligible for participation in this trial, so 
the results should not be generalized to them.
Although the rate of serious adverse events 
did not differ significantly between the ticagrelor 
and aspirin groups, discontinuation of study treat-
ment was more common among patients who 
received ticagrelor. This difference was primarily 
due to dyspnea, which is a known adverse effect 
of ticagrelor treatment.15,17 Other causes of the 
higher rate of discontinuation in the ticagrelor 
group were minor and minimal bleeding events.
In conclusion, in our trial involving patients 
with acute ischemic stroke or transient ischemic 
attack, ticagrelor was not found to be superior to 
aspirin in reducing the risk of the composite end 
point of stroke, myocardial infarction, or death.
Supported by AstraZeneca.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
References
1. Johnston SC, Gress DR, Browner WS, 
Sidney S. Short-term prognosis after 
emergency department diagnosis of TIA. 
JAMA 2000; 284: 2901-6.
2. Coull AJ, Lovett JK, Rothwell PM. 
Population based study of early risk of 
stroke after transient ischaemic attack or 
minor stroke: implications for public edu-
cation and organisation of services. BMJ 
2004; 328: 326.
3. Giles MF, Rothwell PM. Risk of stroke 
early after transient ischaemic attack: 
a systematic review and meta-analysis. 
Lancet Neurol 2007; 6: 1063-72.
4. Wu CM, McLaughlin K, Lorenzetti 
DL, Hill MD, Manns BJ, Ghali WA. Early 
risk of stroke after transient ischemic at-
tack: a systematic review and meta-analy-
sis. Arch Intern Med 2007; 167: 2417-22.
5. Kernan WN, Ovbiagele B, Black HR, 
et al. Guidelines for the prevention of 
stroke in patients with stroke and tran-
sient ischemic attack: a guideline for 
healthcare professionals from the Ameri-
can Heart Association/American Stroke 
Association. Stroke 2014; 45: 2160-236.
6. International Stroke Trial Collabora-
tive Group. The International Stroke Trial 
(IST): a randomised trial of aspirin, sub-
cutaneous heparin, both, or neither among 
19435 patients with acute ischaemic stroke. 
International Stroke Trial Collaborative 
Group. Lancet 1997; 349: 1569-81.
7. CAST (Chinese Acute Stroke Trial) 
Collaborative Group. CAST: randomised 
placebo-controlled trial of early aspirin use 
in 20,000 patients with acute ischaemic 
stroke. Lancet 1997; 349: 1641-9.
8. Antithrombotic Trialists’ (ATT) Collab-
oration, Baigent C, Blackwell L, et al. Aspi-
rin in the primary and secondary prevention 
of vascular disease: collaborative meta-analy-
sis of individual participant data from ran-
domised trials. Lancet 2009; 373: 1849-60.
9. Valkhoff VE, Sturkenboom MC, Hill 
C, Veldhuyzen van Zanten S, Kuipers EJ. 
Low-dose acetylsalicylic acid use and the 
risk of upper gastrointestinal bleeding: 
a meta-analysis of randomized clinical 
trials and observational studies. Can J 
Gastroenterol 2013; 27: 159-67.
10. Wang Y, Wang Y, Zhao X, et al. Clopi-
dogrel with aspirin in acute minor stroke 
or transient ischemic attack. N Engl J Med 
2013; 369: 11-9.
11. The ESPRIT Study Group. Aspirin plus 
dipyridamole versus aspirin alone after ce-
rebral ischaemia of arterial origin (ESPRIT): 
randomised controlled trial. Lancet 2006; 
367: 1665-73.
12. Husted S, Emanuelsson H, Heptin-
stall S, Sandset PM, Wickens M, Peters G. 
Pharmacodynamics, pharmacokinetics, 
and safety of the oral reversible P2Y12 an-
tagonist AZD6140 with aspirin in patients 
with atherosclerosis: a double-blind com-
parison to clopidogrel with aspirin. Eur 
Heart J 2006; 27: 1038-47.
13. Storey RF, Husted S, Harrington RA, 
et al. Inhibition of platelet aggregation by 
AZD6140, a reversible oral P2Y12 receptor 
antagonist, compared with clopidogrel in 
patients with acute coronary syndromes. 
J Am Coll Cardiol 2007; 50: 1852-6.
14. Johnston SC, Amarenco P, Albers GW, 
et al. Acute Stroke or Transient Ischemic 
Attack Treated with Aspirin or Ticagrelor 
and Patient Outcomes (SOCRATES) trial: 
rationale and design. Int J Stroke 2015; 10: 
1304-8.
15. Wallentin L, Becker RC, Budaj A, et al. 
Ticagrelor versus clopidogrel in patients 
with acute coronary syndromes. N Engl J 
Med 2009; 361: 1045-57.
16. Amarenco P, Lavallée PC, Labreuche J, 
et al. One-year risk of stroke after tran-
sient ischemic attack or minor stroke. 
N Engl J Med 2016; 374: 1533-42.
17. Bonaca MP, Bhatt DL, Cohen M, et al. 
Long-term use of ticagrelor in patients 
with prior myocardial infarction. N Engl J 
Med 2015; 372: 1791-800.
Copyright © 2016 Massachusetts Medical Society.
Figure 3 (facing page). Hazard Ratios for the Primary 
End Point According to Predefined Subgroups.
The body-mass index (BMI) is the weight in kilograms 
divided by the square of the height in meters. National 
Institutes of Health Stroke Scale (NIHSS) scores range 
from 0 to 42, with higher scores indicating more severe 
stroke. NA denotes not applicable (sample too small), 
and TIA transient ischemic attack.
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